Graig Suvannavejh

George Farmer

Jonathan Chang

Marc Frahm

Paul Jeng

Tony Butler

Yu He

Alexandre Bouilloux

Michael Kim

Peter Lawson

Yanan Zhu

Arthur He

Matthew Cowper

Michael Klem

Michael Schmidt

Quan Ang

- **Adaptimmune Therapeutics plc** received a notice from Nasdaq on **September 11, 2025**, indicating that its Market Value of Listed Securities (MVLS) was below the **$35.0 million** minimum required for continued listing on The Nasdaq Capital Market.  **[1621227_0001104659-25-089558_adap-20250911x8k.htm:1]** 
- The company's MVLS has been below this threshold for the last **32 consecutive business days**, and it also did not meet alternative listing standards related to stockholders' equity or net income.  **[1621227_0001104659-25-089558_adap-20250911x8k.htm:1]** 
- Adaptimmune Therapeutics has **180 calendar days**, until **March 10, 2026**, to regain compliance by maintaining an MVLS of at least **$35.0 million** for ten consecutive business days.  **[1621227_0001104659-25-089558_adap-20250911x8k.htm:1]** 
- Failure to regain compliance by the deadline will result in the company's American Depositary Shares (ADSs) being subject to delisting from Nasdaq.  **[1621227_0001104659-25-089558_adap-20250911x8k.htm:1]**

Adaptimmune Therapeutics Receives Nasdaq Delisting Notice

Adaptimmune Therapeutics (ADAP)